Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 20/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.47 |
| ▸ | FYN | P06241 | 3/20 | 0.47 |
| ▸ | YES1 | P07947 | 3/20 | 0.47 |
| ▸ | SRC | P12931 | 3/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | RAB29 | O14966 | 1/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620858 | 0.88 | AURKA (0.51) | AURKACYP3A4CYP1A2CYP2C9FYN | |
| SCHEMBL1623211 | 0.88 | AURKA (0.46) | AURKACYP3A4CYP1A2CYP2C9FYN | |
| SCHEMBL1623742 | 0.83 | AURKA (0.61) | AURKACYP3A4CYP1A2CYP2C9FYN | |
| SCHEMBL1622443 | 0.79 | AURKA (0.51) | AURKACYP3A4CYP1A2CYP2C9FYN | |
| SCHEMBL1620867 | 0.77 | AURKA (0.48) | AURKACYP3A4CYP1A2CYP2C9FYN | |
| SCHEMBL1621945 | 0.72 | AURKA (0.46) | AURKACYP3A4CYP1A2CYP2C9FYN | |
| SCHEMBL1623919 | 0.70 | AURKA (0.46) | AURKACYP3A4CYP1A2CYP2C9FYN | |
| SCHEMBL1622247 | 0.69 | AURKA (0.47) | AURKACYP3A4CYP1A2CYP2C9FYN | |
| SCHEMBL12754344 | 0.69 | AURKA (0.46) | AURKACYP3A4CYP1A2CYP2C9FYN | |
| SCHEMBL1623989 | 0.69 | AURKA (0.47) | AURKACYP3A4CYP1A2CYP2C9FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090292121-A1 | Cyanopyridine derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292121-A1 | Cyanopyridine derivative and use thereof as medicine | DPYD, IDH1, TP53 | AURKA 172/4885CYP3A4 177/4885CYP1A2 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.